Goldman Sachs reports 3.9% stake in agilon health
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC report beneficial ownership of 651,825.59 shares of agilon health, inc. common stock, representing 3.9% of the class as of 06/30/2026.
Rhea-AI Filing Summary
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC report beneficial ownership of 651,825.59 shares of agilon health, inc. common stock, representing 3.9% of the class as of 06/30/2026. All reported shares are held with shared voting and shared dispositive power, with no sole voting or dispositive power. The filing is an amendment and confirms that Goldman Sachs & Co. LLC is the registered broker-dealer and investment adviser subsidiary through which the securities are held. The Goldman Sachs reporting units also disclaim beneficial ownership for certain client and fund-related holdings as described in the exhibits.
Key Figures
Key Terms
beneficial ownership financial
parent holding company financial
disclaim beneficial ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in agilon health (AGL) does Goldman Sachs report in this Schedule 13G/A?
Why is Goldman Sachs’ ownership in agilon health (AGL) below 5% in this filing?
Which Goldman Sachs entities are listed as beneficial owners of agilon health (AGL) stock?
What disclaimers does Goldman Sachs include about its agilon health (AGL) beneficial ownership?
What is the relationship between The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC in the AGL filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.